Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
13.26 USD | +1.69% | +2.39% | -11.01% |
01/04 | Elanco Animal Health Appoints Two Ancora Holdings' Nominees to Board | MT |
01/04 | Elanco appoints two directors after settling with activist Ancora | RE |
Summary
- Overall, and from a short-term perspective, the company presents an interesting fundamental situation.
Strengths
- The company's share price in relation to its net book value makes it look relatively cheap.
- The company has a low valuation given the cash flows generated by its activity.
- For the last 4 months, the company has been enjoying highly positive EPS revisions, which were frequently and significantly raised.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
Weaknesses
- According to forecast, a sluggish sales growth is expected for the next fiscal years.
- The company has insufficient levels of profitability.
- One of the major weak points of the company is its financial situation.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-11.01% | 6.54B | B- | ||
-19.73% | 72.39B | B+ | ||
+15.88% | 3.43B | B- | ||
-0.68% | 1.4B | - | ||
-17.27% | 1.34B | B | ||
-2.73% | 1.26B | - | ||
-28.16% | 1.2B | C- | ||
-14.67% | 1.12B | - | ||
-5.37% | 990M | - | ||
-24.06% | 805M | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- ELAN Stock
- Ratings Elanco Animal Health Incorporated